Compass Pathways reports Q3 2026 loss, strong cash and prepares NDA filing for COMP360 launch
Compass Pathways plc posted a GAAP loss of $0.31 per share for the third quarter of 2026, beating analysts’ expectations by $0.10. The company disclosed $444 million in cash at quarter‑end and said the rolling NDA submission for its psilocybin‑based depression therapy COMP360 will be completed within two weeks, targeting a first‑half‑2027 launch pending FDA approval. Research and development expenses fell to $23.5 million for the three‑month period, while operating expenses were $56 million for the quarter.
Why it matters
The cash balance is expected to fund operations through 2028, giving the company runway to commercialize COMP360 if the FDA approves it. The upcoming NDA filing and anticipated H1‑2027 launch could create a new blockbuster revenue stream in the treatment‑resistant depression market.
Key facts
- 1GAAP EPS of -$0.31, beating estimates by $0.10. seekingalpha.com
- 2Cash of $444 million at the end of the third quarter. sec.gov
- 3Launch readiness on track for expected launch in H1 2027, subject to FDA approval. sec.gov
- 4Rolling NDA submission to be completed within the next two weeks. seekingalpha.com
- 5Research and development expenses of $23.5 million for the three months ended September 30, 2026. sec.gov
- 6Operating expenses of $56 million for the quarter. investing.com
Summary written by AlphAI AI Desk from 10 of 10 sources. Not investment advice. Figures are as stated by the linked sources.